Compositions and methods for treatment of hepatitis C virus-associated diseases
US6995146B2 · kind B2 · utility
24Cited by
12References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 2001 |
| Grant date | Feb 7, 2006 |
| Priority date | — |
| Expiry date | Nov 17, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24222
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.